Opinion|Videos|September 3, 2025
Highlighting Deuruxolitinib for Alopecia Areata
Panelists discuss how deuruxolitinib, evaluated in the THRIVE-AA1 and THRIVE-AA2 phase 3 trials, differs from previous Janus kinase (JAK) inhibitors in its formulation and efficacy, and why ensuring long-term patient adherence through 24 weeks is crucial for treatment durability and success.
Advertisement
Video content above is prompted by the following:
- Mostaghimi: Deuruxolitinib has been evaluated in the
THRIVE-AA1 andTHRIVE-AA2 multinational phase 3 clinical trials gaining FDA approval in 2024. How did this JAK inhibitor differ from the last past two 2 JAK inhibitors approved in the previous 2 years?- Durability is often an issue seen in studies where patients don’t remain on therapies long-term. Why is it so important to see the majority of patients staying on deuruxolitinib through 24 weeks?
- How does the durability of the different JAK inhibitors compare?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Atopic Dermatitis Clinical Trial Representation: Addressing Historical Gaps
September 19th 2025
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025
- Rapid Therapeutic Effects Seen With a JAK Inhibitor
September 17th 2025
- SALT Scoring for Alopecia Areata
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Use of Subcutaneous Pembrolizumab for NSCLC
2
Iron Dysregulation Linked to MS Progression, Review Finds
3
FDA Approves Ruxolitinib Cream for Patients as Young as 2 Years With Atopic Dermatitis
4
Early Linvoseltamab Use Prevents Myeloma Progression: Paula Rodríguez-Otero, MD, PhD
5